Joshua Riggs's most recent trade in Insight Molecular Diagnostics Inc. was a trade of 47,170 Restricted Stock Units done . Disclosure was reported to the exchange on March 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc | Joshua Riggs | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2026 | 47,170 | 141,509 | - | - | Restricted Stock Units | |
| Insight Molecular Diagnostics Inc | Joshua Riggs | Director, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2026 | 47,170 | 50,675 (0%) | 0% | - | Common Stock | |
| Insight Molecular Diagnostics Inc | Joshua Riggs | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 26 Mar 2026 | 12,310 | 38,365 (0%) | 0% | 4.1 | 50,594 | Common Stock |
| Insight Molecular Diagnostics Inc | Joshua Riggs | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2025 | 400,000 | 400,000 | - | - | Option to Purchase Common Stock | |
| Insight Molecular Diagnostics Inc | Joshua Riggs | CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 188,679 | 188,679 | - | - | Restricted Stock Units | |
| Insight Molecular Diagnostics Inc | Joshua Riggs | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 90,000 | 90,000 | - | - | Option to Purchase Common Stock | |
| Insight Molecular Diagnostics Inc | Joshua Riggs | Director, CEO and President | Purchase of securities on an exchange or from another person at price $ 2.95 per share. | 11 Apr 2024 | 3,390 | 3,505 (0%) | 0% | 3.0 | 10,001 | Common Stock, no par value |
| Insight Molecular Diagnostics Inc | Joshua Riggs | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 40,000 | 40,000 | - | - | Option to Purchase Common Stock | |
| Insight Molecular Diagnostics Inc | Joshua Riggs | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 800,000 | 800,000 | - | - | Option to Purchase Common Stock | |
| Insight Molecular Diagnostics Inc | Joshua Riggs | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 350,000 | 350,000 | - | - | Option to Purchase Common Stock | |
| Insight Molecular Diagnostics Inc | Joshua Riggs | CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 116,426 | 116,426 | - | - | Option to Purchase Common Stock | |
| Insight Molecular Diagnostics Inc | Joshua Riggs | Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 257,485 | 257,485 | - | - | Option to Purchase Common Stock |